Compare Dropbox Inc (DBX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs TG Therapeutics Inc — how do they compare? Dropbox Inc trades at $34.42 (market cap $7.42B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Dropbox Inc and TG Therapeutics Inc are close in size by market cap, and Dropbox Inc is more actively traded (3,061,580 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and TG Therapeutics Inc for 16 Days on average.
| DBX | TGTX | |
|---|---|---|
Market Cap | $7.42B | $8.16B |
Volume | 3,061,580 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $37.74 | $59.06 |
52-Week Low | $22.06 | $26.94 |
Typical Hold Time | 97 Days | 16 Days |
Enterprise Value | $10.29B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.36, up 3.87% with bullish technical signals and consistent earnings beats. The company maintains strong profitability with 79.72% gross margins and 20.16% net income margin, though revenue growth remains flat near $2.5B. Recent news highlights insider selling and a security breach affecting 5,000 accounts, while analyst sentiment is divided with a $26.83 consensus target below current price.
The outlook is mixed with solid fundamentals but concerning valuation and insider activity. Investment opportunity lies in sustained profitability and AI integration potential, while risks include stagnant growth, high debt levels, and negative shareholder equity. Wall Street remains cautious with equal buy/hold/sell distribution.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
